GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Deitmar Berger effective as of May 7, 2018.
The compensation committee of Atara's board of directors granted Dr. Berger a stock option to purchase 85,000 shares of Atara’s common stock, and restricted stock units to acquire 50,000 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Dr. Berger entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $42.05, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 7, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
